Cantor Fitzgerald CEO Howard Lutnick Makes Case For Trump At MSG Rally During a rally at Madison Square Garden, CEO of Cantor ...

Cantor Fitzgerald analyst Deepak Mathivanan maintained a Buy rating on Meta Platforms (META – Research Report) yesterday and set a price ...

Cantor Fitzgerald and Silverstein Properties have topped off Shorehaven, the first phase of South Pier, a $1.8 billion mixed-use development on Tempe Town Lake in Tempe, Ariz. The master-planned ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Cantor Fitzgerald raised the firm’s price target on MicroStrategy (MSTR) to $312 from $200 and keeps an Overweight rating on the shares. MicroStrategy, whose core business is being a business ...

Cantor Fitzgerald came out and argued on Monday morning that short-term market bullishness should hold especially with a stimulus coming from the upcoming U.S. presidential election, but bigger ...

Cantor Equity Partners I, a special purpose acquisition company affiliated with Cantor Fitzgerald, filed for a $200 million initial public offering. Howard Lutnick, chairman and chief executive ...

Cantor Fitzgerald raised the firm’s price target on Teladoc (TDOC) to $11 from $10 and keeps an Overweight rating on the shares. The firm expects the stock will see some relief following the ...

https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-price-target-raised-to-20-from-16-at-piper-sandler Cantor Fitzgerald raised the firm’s price target on ...

Cantor Fitzgerald recently raised the price target on the stock to $225 from $200 and kept an Overweight rating on the shares into Q3 earnings season. The investment firm sees a tale of two ...

Tuesday, Cantor Fitzgerald initiated coverage on Hive Digital Technologies (NASDAQ:HIVE) shares with an Overweight rating and a 12-month price target of $9.00. The firm highlighted HIVE's status ...

On Monday, Cantor Fitzgerald maintained a positive stance on shares of HCA Healthcare Inc (NYSE: NYSE:HCA), raising the price target to $405 from the previous target of $392, while keeping an ...